• Scientists test G. vaginalis treatment


Scientists test G. vaginalis treatment

Nov 08 2011

Posted by Neil Clark

Scientists have used quantitative analysis processes to determine whether neutralising recombinant antibodies will become a novel treatment for in bacterial vaginosis.

In a study published by BMC Biotechnology journal, a team from Lithuania noted that bacterial vaginosis is often caused by gardnerella vaginalis colonising the vaginal tract, which produces protein toxin vaginolysin (VLY).

Inhibition of VLY-mediated cell lysis by antibodies may have important physiological relevance., with the team suggesting that recombinant single-chain antibodies may have the desired effect.

Using quantitative analysis processes, the scientists tested the antigen-binding activity of purified single-chain variable fragments of immunoglobulins (scFvs) and calculated apparent Kd values and found that the neutralizing potency of scFvs were in agreement with those of parental full-length antibodies.

"G. vaginalis caused infections continue to be a worldwide problem, therefore neutralizing recombinant antibodies may provide novel therapeutic agents useful in the treatment of bacterial vaginosis and other diseases caused by G. vaginalis," the report noted.

Digital Edition

Chromatography Today - Buyers' Guide 2022

December 2021

In This Edition Modern & Practocal Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions


Lab Asia 2023

Oct 10 2023 Hybrid event

MicroTAS 2023

Oct 15 2023 Katowice, Poland

ISPPP 2023

Nov 05 2023 Vienna, Austria

SETAC North America

Nov 12 2023 Louisville, KY, USA

Eastern Analytical Symposium

Nov 13 2023 Plainsboro, NJ, USA

View all events